It was found that eseridine, physostigmine, physovenine, and eseramine can be predicted with a probability Pa of more than 0.5 for their dual MOAs (inhibition of acetylcholinesterase and butyrylcholinesterase) and pharmacological effects related to the treatment of VaD (cognition disorder treatment and nootropic). This evidence concerns the gene ACHE and cognitive disorder.